Results 131 to 140 of about 351,954 (346)

mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein [PDF]

open access: diamond, 2015
Tommasina Guglielmelli   +8 more
openalex   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population

open access: yesClinical Anatomy, EarlyView.
ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley   +1 more source

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment

open access: yes
American Journal of Hematology, EarlyView.
Ghulam Rehman Mohyuddin   +3 more
wiley   +1 more source

Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Since 2016, the China National Medical Products Administration (NMPA) has reformed its drug registration classification rules and defines the innovative drugs as new drugs that have not been marketed domestically and overseas. This study sought to systematically evaluate the characteristics of the innovative drugs approved in China. The cross‐sectional
Xingyue Zhu, Die Xiao
wiley   +1 more source

Should prophylactic granulocyte‐colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide‐based therapy? [PDF]

open access: bronze, 2007
María‐Victoria Mateos   +4 more
openalex   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy   +15 more
wiley   +1 more source

Impacts of Diets and Food Plans in Health and Diseases—A Narrative Review

open access: yesFood Safety and Health, EarlyView.
This review emphasizes different diet types, providing insights into their nutritional content and health effects. Vegetarian and vegan diets, ketogenic diets, Mediterranean diets, Western diets, pescatarian diets, flexitarian diets, and territorial diversified diets are discussed, highlighting their influences on health, and diseases.
Md. Mahbubar Rahman   +3 more
wiley   +1 more source

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications

open access: yesBlood Cancer Journal, 2021
Hiroto Ohguchi   +2 more
doaj   +1 more source

Role of minimal residual disease assessment in multiple myeloma

open access: yesHaematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy